U.S. BCG Vaccine Recommendations for Tuberculosis Control

A joint statement updates previous recommendations on Bacillus Calmette-Guérin (BCG) vaccine use for tuberculosis (TB) control in the United States. The report was issued by CDC, the Advisory Committee for the Elimination of Tuberculosis, and the Advisory Committee on Immunization Practices. It summarizes current considerations regarding BCG vaccination, prompted by a resurgence of TB cases and new meta-analyses on vaccine efficacy.

Use Cases

• Analyzing shifts in U.S. public health strategy based on updated BCG vaccine efficacy data mentioned in the description
• Studying policy recommendations for high-risk groups like infants, children, and healthcare workers described in the report
• Comparing primary TB control strategies (early identification/treatment) versus secondary strategies (latent infection therapy) outlined in the document

Strengths

• Report is a formal joint statement from multiple U.S. public health advisory committees
• Description references specific meta-analyses confirming >80% protective efficacy against serious TB in children
• Document outlines a clear primary and secondary strategy for TB prevention and control in the U.S.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

Centers for Disease Control and Prevention (CDC), Advisory Council for the Elimination of Tuberculosis, Advisory Committee on Immunization Practices

Collection Method

Policy analysis and synthesis of clinical trial data and case-control studies

Geography

United States